Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

The post Oral GLP-1 Obesity Drugs Near Wider Access appeared first on Considerable.

The global obesity care landscape is on the cusp of a major transformation. The year 2026 is expected to bring in the most powerful generation of anti-obesity medications ever developed. Building on ...

Research has shown that people who stop taking GLP-1 drugs, such as Ozempic and Wegovy, typically experience weight regain ...

With access to unhealthy food soaring and physical activity levels declining, the World Obesity Federation predicts that between 2020 and 2035, Europe and Central Asia will experience a 61% increase ...

"During the aging process, we begin to lose muscle," typically half a percent to 1 percent of muscle weight per year, said ...

From changing the definition to the rise of GLP-1 medications, and especially Prime Minister Narendra Modi’s clarion call against obesity ...

January 8, 2026 - By Amy Anderson - Adults aged 65 and older's desire to lose weight is frequently centered around improving functional ability and health outcomes, which may differ from those of ...

NEW DELHI – Obesity emerged as a central focus of public health policy in India in 2025, driven by a major overhaul of clinical definitions, a surge in new weight loss medications and a series of ...

BioAge Labs is developing a promising weight management candidate. The medicine could have several advantages over approved anti-obesity drugs. However, BioAge is an early-stage biotech whose ...

Weight regain after discontinuation of tirzepatide was accompanied by a reversal of cardiometabolic improvements in a post-hoc analysis. For waist circumference, systolic blood pressure, and HbA1c ...

With generic versions of the weight-loss drug Ozempic expected to hit the Canadian market this year, provincial data shows ...